Med by Cell Press
@MedCellPress
Followers
13K
Following
200
Media
254
Statuses
939
Medical journal publishing research with immediate impact on clinical practice and health policy. This account is not monitored, and content is automated.
Joined December 2019
We are turning this account into a fully automated page. To learn more of what’s going on in our journal, follow us on LinkedIn:
1
0
0
Don’t miss #CSStemCells2025 keynotes.🔹Felicia Pagliuca (@VertexPharma): Stem cell derived islets for type 1 diabetes.🔹Malin Parmar (@lunduniversity): Developing a stem cell–based therapy for Parkinson’s disease.Register before Sept 5 for early bird rates.
0
0
0
Online Now: Anti-PD-1 antibody plus anlotinib vs. anlotinib alone in patients with refractory chondrosarcoma: A multicenter, non-randomized phase 2 FLAIL-C trial
cell.com
This trial provides the first evidence in a comparative setting for evaluating the activity of anti-PD-1 immunotherapy-based treatments in advanced chondrosarcoma. The combination of an anti-PD-1...
0
0
0
Online Now: Trends and sociodemographic patterns in hypertension prevalence and treatment in China
cell.com
Cao et al. comprehensively estimated the trends in the hypertension prevalence, awareness, treatment, and control and the choice of antihypertensive drugs among Chinese adults. Hypertension prevale...
0
0
0
Early bird rates for @CellSymposia #CSStemCells2025 are here! .Register before Sept. 5 to secure your seat at this hotly anticipated event in LA.👉
0
0
0
Online Now: Short-course-based TNT with or without PD-1 inhibitor for pMMR locally advanced rectal cancer: Phase 2 results of a randomized trial (STELLAR II)
cell.com
In a phase 2 randomized clinical trial, Tang et al. demonstrate the efficacy and safety of adding sintilimab to SCRT-based TNT for patients with pMMR locally advanced rectal cancer. This therapeutic...
0
1
1
Online Now: Utility of circulating tumor DNA in management of diverse renal malignancies: Insights from a case series in adjuvant and recurrent/metastatic settings
cell.com
This case series describes six patients with diverse renal malignancies in whom ctDNA monitoring influenced clinical decision-making and treatment outcomes. The series highlights the potential of...
0
0
0
Online Now: The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity
cell.com
GLP1 receptor agonists are reshaping obesity treatment with substantial weight loss outcomes, but concerns about cost, long-term adherence, and post-treatment support remain. This perspective...
0
0
0
Online Now: Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells
cell.com
Li et al. overcame ovarian cancer resistance and evasion to conventional CAR-T therapy by generating allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells. These CAR-NKT cells showed...
0
0
1
Online Now: Current paradigm of EGFRins20 in non-small cell lung cancer: A long way forward
cell.com
EGFRins20 mutations in lung cancer are resistant to currently available traditional therapy, and while new drugs have been approved, more advancements are needed to improve patient outcomes. Novel...
0
0
2
Online Now: Immune-related adverse events associated with cancer immunotherapy
cell.com
This review explores immune-related toxicities arising from the major immunotherapy classes. By comparing mechanisms, risk factors, and management strategies across therapeutic platforms, the authors...
0
0
0
Looking forward to @UCIrvine Lisa Wagar’s talk “Predicting immunogenicity using human immune organoids”@CellSymposia #CSStemCells25. Want to join her? Submit an abstract before August 1 to be considered for a poster or short talk
0
0
0
Online Now: Recognizing overweight and obesity as chronic diseases and acknowledging root causes
0
0
0
Collection highlight from @MedCellPress: Anti-BCMA CAR-T cell therapy in relapsed/refractory chronic inflammatory demyelinating polyneuropathy.
0
0
1
Online Now: Chimeric antigen receptor T cells in treatment-refractory DAGLA antibody-associated encephalitis
cell.com
Hegelmaier et al. describe the first use of anti-CD19 CAR T cells in refractory DAGLA antibody-associated encephalitis, achieving complete B cell depletion, anti-DAGLA antibody elimination in serum...
0
1
1
Interested in sharing your research at our Cell Symposium in LA?.We're keeping the abstract submission system open for poster and short talk submissions until August 1, 2025. Submit here: @CellSymposia #CSStemCells25
0
0
0
Online Now: Microbiota-derived metabolites: Key modulators of cancer immunotherapies
cell.com
Microbiota-derived metabolites shape immune responses and influence the efficacy and toxicity of cancer immunotherapies, including checkpoint inhibitors, CAR-T cells, and allogeneic stem cell...
0
0
0
Final call: Abstracts for Gene and cell-based therapies are due tomorrow Friday, July 18. Submit now for a chance to present your work at this symposium in LA! @CellSymposia #CSStemCells2025.
0
0
0
Looking forward to hearing from @Thomas_Rando @UCLAstemcell, Gordana-Vunjak-Novakovic @GVNlab @Columbia & Juan Carlos Izpisua Belmonte @altos_labs in our session “Aging and rejuvenation” @CellSymposia #CSStemCells2025. Abstracts due: July 18! .
0
0
0
Online Now: Association of anti-PD-1 therapy with severe radiation-induced oral mucositis: A retrospective cohort study and validation in the CONTINUUM trial
0
0
0
Online Now: Conformational ligand-directed targeting of calcium-dependent receptors in acute trauma
cell.com
Major trauma is a leading cause of death worldwide; however, translational targets have not been systematically identified. Pasqualini et al. identify a repertoire of trauma-homing ligand peptides...
0
0
0